Effect of Individual Reminiscence Therapy in the Elderly People With Neurocognitive Disorders

Sponsor
Rsocialform - Geriatria, Lda (Other)
Overall Status
Completed
CT.gov ID
NCT04658394
Collaborator
(none)
122
13
2
6.6
9.4
1.4

Study Details

Study Description

Brief Summary

This research aims to evaluate the ability of individual reminiscence therapy (RT), using a simple reminiscence format, to improve the overall cognitive function, memory, emotional status and quality of life (QoL) of older adults with neurocognitive disorders (NCD) attending social care and support services. A multicentre randomised controlled trial (RCT) is proposed in Azores archipelago with repeated measures (pre-intervention, post-intervention and follow-up). Intervention group will hold 26 individual RT sessions, twice a week for 13 weeks. Control group participants will maintain their treatment as usual. Make a subsample analysis of the main clinical diagnoses, and compare the results of sample and subsample with a previous study that had the same intervention protocol.

Condition or Disease Intervention/Treatment Phase
  • Other: Reminiscence therapy
N/A

Detailed Description

Neurocognitive disorder (NCD) is one of the main causes of disability among older adults and its prevalence is increasing due to the ageing of the population. It is estimated that globally, neurocognitive disorders affect 44.35 million people and it is expected that by the year 2050 the number of those affected worldwide will triple up to 135.46 million.

The absence of an effective pharmacological treatment that halts or delays the development of the disease has aroused interest in non-pharmacological therapies (NPT) as a complement to pharmacological treatment that can improve the quality of life of people with neurocognitive disorders. One of the most researched NPT and with the greatest tradition in this field is Reminiscence Therapy (RT).

RT implies the discussion of past activities, events and experiences, usually with the help of triggers (e.g., photographs, home objects and other familiar items from the past, music, any object or stimulus) that serve to stimulate memories. In its application to dementias, RT is based on the fact that the memory deficit of people with dementia implies that they are able to remember events from their past life, especially from childhood to early adulthood, but not newer facts. It focuses on preserved capacities and memories, promotes communication and enables the person to connect with his past and recover his sense of personal identity. In this way, the RT can be understood as an intervention on the edge of those of cognitive orientation and those centred on emotion, with potential interactive effects on autobiographical memory and psychological well-being.

In simplified form, there are at least two approaches to RT. The first approach as a "life review" where participants are guided through significant experiences of their biography trying to give meaning to their lives. This type of RT is more structured and is usually conducted in an individual format. It may involve the production of "life books". This approach is considered to have an integrative function aimed at achieving a sense of validation, coherence and reconciliation with one's past. Another approach that call general or simple reminiscence, implies the stimulation of autobiographical memory during conversations on specific themes of the past (e.g, holidays, food and drink, work) using stimulus to trigger memories. It has been described as an unstructured autobiographical memory narration. This reminiscence format can be conducted both individually and in groups and promotes communication between participants who share their memories and stories.

In either format that RT is applied on, the introduction of triggering stimulus (e.g., photographs, music, old objects) to help memory is considered fundamental. These triggers can be generic, reflecting common experiences in the lives of people relevant to their age group (e.g., a school manual can serve as a reminder of the experience during their school stage), or specific, with stimulus related to the person's own experiences (e.g., photographs of an important vital event such as their wedding day or a journey during their youth).

As for the effectiveness of RT, according to a recent review by Cochrane, there is some evidence on its positive effects on cognition, QoL, communication and possibly on the mood of people with dementia, even if the benefits are small. Despite the distinction between the two different approaches to RT (general reminiscence vs. life history), the therapy modality does not seem to be as important to achieve positive effects as the individual or group format of the sessions and the context in which the intervention is administered (people living in the community or institutionalised).

In particular, according to the results of the review study, the RT seems to be able to generate a small benefit on cognitive function immediately after the intervention, although it usually does not continue after a longer follow-up period. Regarding the administration format, the individual RT seems slightly superior in its effects on cognition both immediately and after a follow-up period. In any case, its effects seem comparable to those of other cognitive stimulation modalities.

As for the effect of RT on quality of life (QoL), an individual RT study based on life review, showed an improvement in Qol-AD. The effects with a group modality do not seem consistent, showing little or no effect on QoL, although the key factor may be the context of application (community vs. institution), with better group RT results in institutionalised patients.

In a multicentre study conducted in Portugal with older adults with neurocognitive disorders, in individual format, there was a significant effect on the overall cognition, memory and QoL of the participants.

Group RT was associated with a likely effect on communication both after the intervention and in the follow-up. This effect was not replicated in the individual RT, with uncertain results.

Finally, despite the evidence on the effect of RT on the mood of elderly people without dementia, in the case of people with dementia only a small effect on mood was found for those participating in individual RT. In the portuguese multicentre studies there were no significant differences in depressive symptomatology.

Based on the above, this research proposal aims to evaluate the ability of individual RT within a general reminiscence format, to improve overall cognitive function, in particular memory, emotional state (depression and anxiety) and QoL of older adults with neurocognitive disorders attending social care and support services in the Azores archipelago.

It is proposed to evaluate the efficacy of the intervention in the endpoint assessment and the duration of the effects at three months follow-up. Furthermore, an analysis of results based on the diagnosis of the participants is proposed for those diagnoses with sufficient representation in the sample (more than 20 cases in each group). Additionally, it is proposed to analyze the factors that predict the response to the intervention (responder analysis). Finally, the results of this study will be compared and can be analyzed together with those of a previous study that used the same individual RT program and the same experimental design (clinicaltrials.gov ID: NCT04047238).

Study Design

Study Type:
Interventional
Actual Enrollment :
122 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Effect of Individual Reminiscence Therapy in the Elderly People With Neurocognitive Disorders: A Multicentre Randomised Controlled Trial in Azores Archipelago
Actual Study Start Date :
Feb 11, 2021
Actual Primary Completion Date :
Aug 31, 2021
Actual Study Completion Date :
Aug 31, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intervention Group

Participants who meet the inclusion criteria will be randomly assigned to the intervention group receiving RT or to a control group receiving treatment as usual. Participants in the intervention group will participate in two RT sessions per week for 13 weeks besides their treatment as usual. The sessions will be based on the Book of the Past and the Present and they will follow the same protocol in every participant institution.

Other: Reminiscence therapy
Intervention group will receive two RT sessions per week for 13 weeks. RT sessions will last approximately 50 minutes and will be developed according to the following structure: · Welcome to the patient and reality orientation therapy (7 minutes) · Conducting the main activity of reminiscence (40 minutes) · Closure, thank you for the participation and farewell until the next session (3 minutes) Reminiscence therapy sessions will have an individual format and will be conducted by a therapist previously trained in the protocol and the principles of RT. The Reminiscence activities of each session will be carried out following the protocol proposed in the Book of the Past and the Present.

No Intervention: Control Group

Participants assigned to the control group will maintain their usual treatment in the institution, participating in the activities previously assigned to their individual care plan.

Outcome Measures

Primary Outcome Measures

  1. Cognitive functioning evaluated through Mini-Mental State Examination [MMSE] [baseline]

    Cognitive functioning is assessed using the MMSE which is a gold standard for assessing global cognitive function. Scores range from 0 to 30, with higher scores indicating better cognitive functioning.

  2. Change in cognitive functioning evaluated through Mini-Mental State Examination [MMSE] [13 weeks after the beginning of the intervention]

    Cognitive functioning is assessed using the MMSE which is a gold standard for assessing global cognitive function. Scores range from 0 to 30, with higher scores indicating better cognitive functioning.

  3. Change in cognitive functioning evaluated through Mini-Mental State Examination [MMSE] [12 weeks after end of intervention]

    Cognitive functioning is assessed using the MMSE which is a gold standard for assessing global cognitive function. Scores range from 0 to 30, with higher scores indicating better cognitive functioning.

Secondary Outcome Measures

  1. Quality of life evaluated through Quality of Life - Alzheimer's Disease [QoL-AD] [baseline]

    The QoL-AD is used to assess quality of life. This 13-item scale assesses the quality of life in people diagnosed with dementia, gathering information from the patient about the following domains: perceived health, mood, physical condition, interpersonal relationships, hobbies, decision-making skills, and life as a whole. Scores range from 13 to 52, with higher scores indicating better quality of life. It has good psychometric characteristics and its use has been recommended to evaluate psychosocial interventions.

  2. Change in quality of life evaluated through Quality of Life - Alzheimer's Disease [QoL-AD] [13 weeks after the beginning of the intervention]

    The QoL-AD is used to assess quality of life. This 13-item scale assesses the quality of life in people diagnosed with dementia, gathering information from the patient about the following domains: perceived health, mood, physical condition, interpersonal relationships, hobbies, decision-making skills, and life as a whole. Scores range from 13 to 52, with higher scores indicating better quality of life. It has good psychometric characteristics and its use has been recommended to evaluate psychosocial interventions.

  3. Change in quality of life evaluated through Quality of Life - Alzheimer's Disease [QoL-AD] [12 weeks after end of intervention]

    The QoL-AD is used to assess quality of life. This 13-item scale assesses the quality of life in people diagnosed with dementia, gathering information from the patient about the following domains: perceived health, mood, physical condition, interpersonal relationships, hobbies, decision-making skills, and life as a whole. Scores range from 13 to 52, with higher scores indicating better quality of life. It has good psychometric characteristics and its use has been recommended to evaluate psychosocial interventions.

  4. Anxiety symptomatology assessed through the Geriatric Anxiety Inventory [GAI] [baseline]

    It assesses, in several contexts, the severity of anxiety symptoms in the older adults. It consists in 20 dichotomous response items (I agree/disagree) and refers to the subject's feelings in the week prior to the evaluation. One (1) point is assigned to each agree answer and the overall score is obtained by adding the scores of all items. Scores over 10/11 points indicate symptoms of severe anxiety.

  5. Change in anxiety symptomatology assessed through the Geriatric Anxiety Inventory [GAI] [13 weeks after the beginning of the intervention]

    It assesses, in several contexts, the severity of anxiety symptoms in the older adults. It consists in 20 dichotomous response items (I agree/disagree) and refers to the subject's feelings in the week prior to the evaluation. One (1) point is assigned to each agree answer and the overall score is obtained by adding the scores of all items. Scores over 10/11 points indicate symptoms of severe anxiety.

  6. Change in anxiety symptomatology assessed through the Geriatric Anxiety Inventory [GAI] [12 weeks after end of intervention]

    It assesses, in several contexts, the severity of anxiety symptoms in the older adults. It consists in 20 dichotomous response items (I agree/disagree) and refers to the subject's feelings in the week prior to the evaluation. One (1) point is assigned to each agree answer and the overall score is obtained by adding the scores of all items. Scores over 10/11 points indicate symptoms of severe anxiety.

  7. Mood assessed through the Geriatric Depression Scale-15 [GDS-15] [baseline]

    The GDS-15 is used to measure mood. It is considered a reliable tool to screen depressive symptoms in older people. With a dichotomous format (yes/no answers), this scale assesses depression in older people. Scores range from 0 to 15, with higher scores indicating more severe depressive symptoms.

  8. Change in mood assessed through the Geriatric Depression Scale-15 [GDS-15] [13 weeks after the beginning of the intervention]

    The GDS-15 is used to measure mood. It is considered a reliable tool to screen depressive symptoms in older people. With a dichotomous format (yes/no answers), this scale assesses depression in older people. Scores range from 0 to 15, with higher scores indicating more severe depressive symptoms.

  9. Change in mood assessed through the Geriatric Depression Scale-15 [GDS-15] [12 weeks after end of intervention]

    The GDS-15 is used to measure mood. It is considered a reliable tool to screen depressive symptoms in older people. With a dichotomous format (yes/no answers), this scale assesses depression in older people. Scores range from 0 to 15, with higher scores indicating more severe depressive symptoms.

  10. Executive functions evaluated throught Frontal Assessment Battery [FAB] [baseline]

    The FAB is used to assess executive function in several subtests: conceptualization, mental flexibility, motor programming, sensitivity to interference, inhibitory control, and environmental autonomy. Scores range from 0 to 18, with higher scores indicating better executive functioning.

  11. Change in executive functions evaluated throught Frontal Assessment Battery [FAB] [13 weeks after the beginning of the intervention]

    The FAB is used to assess executive function in several subtests: conceptualization, mental flexibility, motor programming, sensitivity to interference, inhibitory control, and environmental autonomy. Scores range from 0 to 18, with higher scores indicating better executive functioning.

  12. Change in executive functions evaluated throught Frontal Assessment Battery [FAB] [12 weeks after end of intervention]

    The FAB is used to assess executive function in several subtests: conceptualization, mental flexibility, motor programming, sensitivity to interference, inhibitory control, and environmental autonomy. Scores range from 0 to 18, with higher scores indicating better executive functioning.

  13. Memory function evaluated through Memory Alteration Test [MAT] [baseline]

    The MAT is used to assess memory function. It is an easy and quick instrument that assesses five memory domains: temporal orientation, encoding, semantic memory, free recall, and cued recall. Total scores range from 0 to 50, with higher scores indicating better memory. It has good psychometric properties and is highly sensitive to mild cognitive decline.

  14. Change in memory function evaluated through Memory Alteration Test [MAT] [13 weeks after the beginning of the intervention]

    The MAT is used to assess memory function. It is an easy and quick instrument that assesses five memory domains: temporal orientation, encoding, semantic memory, free recall, and cued recall. Total scores range from 0 to 50, with higher scores indicating better memory. It has good psychometric properties and is highly sensitive to mild cognitive decline.

  15. Change in memory function evaluated through Memory Alteration Test [MAT] [12 weeks after end of intervention]

    The MAT is used to assess memory function. It is an easy and quick instrument that assesses five memory domains: temporal orientation, encoding, semantic memory, free recall, and cued recall. Total scores range from 0 to 50, with higher scores indicating better memory. It has good psychometric properties and is highly sensitive to mild cognitive decline.

Other Outcome Measures

  1. Sociodemographic information gathered through the sociodemographic questionnaire [baseline]

    Participants' answers in the sociodemographic questionnaire designed specifically for this study. It gathers information about gender, age, marital status, formal education, which social response the participant attends, medical comorbidities and cognitive symptoms and will be administered to all participants.

  2. Functional dependence evaluated through Barthel Index [IB] [before baseline (exclusion criteria)]

    This is a 10-item self-administered scale that evaluates the functional capacity to conduct daily life activities. The activities are quoted differently, 0, 1, 2 or 3 points can be assigned. The total score ranges from 0 (totally dependent) to 20 (totally independent), with a total of 0-8 being total dependency; 9-12 being serious dependency; 13-19 being moderate dependency; 20 being total independence. This instrument has item-total correlations between .66 and .93, and has a high internal consistency (Cronbach alpha of .96).

Eligibility Criteria

Criteria

Ages Eligible for Study:
65 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Having a formal diagnosis of a neurocognitive disorder according to Diagnostic and Statistical Manual of Mental Disorders, fifth edition [DSM-5] criteria (participants diagnosis will be confirm in their health records at the institution).

  • Having delivered the informed consent form, duly completed and signed, after prior information.

  • Being able to communicate and understand.

  • Possibility of gathering information about the participant's life history through family members or usual caregivers, using the socio-family questionnaire designed for that purpose.

  • Being 65 years of age or older.

  • Being a native Portuguese speaker.

  • Regularly attending an institution that provides social care and support services for older adults (including people living in long-term care centres, people attending day and social centres and people receiving home support services).

Exclusion Criteria:
  • Suffering from an acute or severe illness that prevent participation in the intervention sessions.

  • Severe sensory and physical limitations that prevent participation.

  • Low level of consciousness and minimal attention span.

  • Presence of severe neuropsychiatric symptoms, such as agitation, psychosis, severe depressive and anxiety symptoms, apathy, or presence of uncontrolled delirium that prevent participation in the sessions.

  • Traumatic life history or marked by adverse events that discourage participation in RT sessions; history of adverse reactions during RT sessions or similar activities.

  • Have a serious or total functional dependence (assessed through the Barthel index).

Contacts and Locations

Locations

Site City State Country Postal Code
1 Rsocialform - Geriatria, Lda. Mealhada Aveiro Portugal 3050-387
2 Santa Casa da Misericórdia da Horta Horta Faial Portugal 9900-033
3 Santa Casa da Misericórdia de Santa Cruz das Flores Santa Cruz das Flores Flores Portugal
4 Santa Casa da Misericórdia de Lajes do Pico Lajes Pico Portugal 9930-126
5 Santa Casa da Misericórdia da Madalena do Pico Madalena Pico Portugal 9950-322
6 Santa Casa da Misericórdia de Vila do Porto Vila do Porto Santa Maria Portugal 9580-528
7 Santa Casa da Misericórdia da Calheta Calheta São Jorge Portugal 9850-070
8 Casa de Repouso João Inácio de Sousa Velas São Jorge Portugal 9800-559
9 Casa do Povo de Arrifes Arrifes São Miguel Portugal 9500-377
10 Casa do Povo da Maia Maia São Miguel Portugal 9625-320
11 Lar Luis Soares de Sousa de Ponta Delgada Ponta Delgada São Miguel Portugal
12 Santa Casa da Misericórdia de Angra do Heroísmo Angra Do Heroísmo Terceira Portugal 9700-020
13 Lar D. Pedro V Praia Da Vitória Terceira Portugal 9760-438

Sponsors and Collaborators

  • Rsocialform - Geriatria, Lda

Investigators

  • Principal Investigator: Susana I Justo Henriques, PhD, Nursing School of Coimbra
  • Principal Investigator: Enrique Pérez Sáez, PhD, National Reference Centre for Alzheimer's and Dementia Care, Imserso, Spain
  • Principal Investigator: João L. Alves Apóstolo, PhD, Nursing School of Coimbra

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Rsocialform - Geriatria, Lda
ClinicalTrials.gov Identifier:
NCT04658394
Other Study ID Numbers:
  • 21112020
First Posted:
Dec 8, 2020
Last Update Posted:
Sep 1, 2021
Last Verified:
Jan 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Rsocialform - Geriatria, Lda
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 1, 2021